A&M Perspectives: How asset light pharmaceutical companies can augment value creation in a disrupted market environment
Over the past two decades, originator pharmaceutical businesses have increasingly disposed of late-stage drug portfolios to third parties. This has spurred the growth of asset-light pharmaceutical companies with radically different operating models. Operating through networks of Contract Development and Manufacturing Organisations (CDMOs), these businesses avoid major capital expenditure, have greater flexibility, and can therefore focus on critical capabilities such as supply chain excellence, market authorisation and technical transfers.
While there are advantages, asset-light models are complex. Many different partners are involved, comprising of specialised CDMOs, distribution partners and a mix of in-house sales and country distributors. This leads to challenges related to demand planning, inventory control and cost control.
At the same time, asset-light pharma businesses are having to respond to global challenges including rising inflation, supply chain disruptions, Covid-19 outbreaks and growing geopolitical tensions.
Based on our experiences of delivering change for a range of asset-light pharmaceutical companies across Europe, we recommend five levers of value creation.
Five value levers for asset-light pharmaceutical businesses
- CDMO rationalisation and technical transfer excellence
- S&OP/ IBP upgrades
- Inventory and working capital optimisation
- Logistics simplification
- Digital tools deployment (commercial focus)
Download
Related Insights
Shocks to global supply chains are increasing in frequency and severity. Russia’s invasion of Ukraine, new Covid outbreaks in China and rising interest rates in the US are occurring at once with ramifications for global trade. What steps can companies take to improve supply chain resilience.
Medical Device Supply Chains: Disruption Is Permanent. Is the Industry Ready?
June 18, 2026
Medical device supply chains are under increasing pressure as global disruption becomes a constant rather than an exception. From geopolitical volatility to material scarcity and regulatory complexity, the sector now operates in an environment where even minor shocks can have far-reaching consequences. This article explores the structural vulnerabilities shaping today’s MedTech supply networks and highlights why traditional approaches are no longer sufficient. It outlines how leading organisations are rethinking resilience not just as risk mitigation, but as a source of competitive advantage in an increasingly unpredictable world. Download the full article to uncover the strategies that are helping companies respond faster, protect patient outcomes, and maintain operational continuity.
Episode 2: Don Antonucci, President and CEO, Providence Health Plan
June 16, 2026
In this episode, Don Antonucci, President and CEO of Providence Health Plan joins A&M Healthcare Industry Group's Craig Savage and Mike Epstein to share how health plans can maintain stability while delivering value to members.
Building AI from Within at Nebraska Medicine
May 28, 2026
What if the real advantage isn’t buying the latest solution, but building your own? Michael Hasselberg, Chief Transformation and Digital Officer at Nebraska Medicine joins A&M Healthcare Industry Group's Seth Ciabotti and Travis Sherman to share how Nebraska Medicine is building AI capabilities internally—from assembling in-house data science and engineering teams to deploying enterprise tools that address real operational pain points.
Medical Management Is Broken Getting AI Right Will Decide Which Plans Survive
May 7, 2026
AI is reshaping medical management from a cost center into a strategic engine for health plans. In this paper, Managing Directors Bryan Komornik and Craig Savage outline where AI is delivering real value today and how plans can modernize clinical operations to improve cost, quality, and experience.
